CytomX Therapeutics Inc (CTMX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.54-3.01%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Sustain revenue growth above 5% quarterly: rev -92.0% vs 5.0%.
CytomX is growing revenue fast, from $0.66M to $10.26M in one quarter. The company improved its operating loss by $8.26M recently. It has a strong partnership with Regeneron to develop cancer therapies. These show progress in its turnaround efforts.
CytomX is still losing money with no profit in sight. Analysts expect revenue to shrink about 2.5% next year. The stock is down 21.5% from its high, reflecting market doubts. The turnaround may stall or fail.
The market prices in a 2.5% revenue decline and a 45% discount to our fair value near $7. Our fair value is 39% below the Street median, reflecting skepticism. We see some recovery potential but risk remains high.
Breaks if: operating loss fails to improve by $5M QoQ
Breaks if: quarterly revenue growth falls below 5% QoQ
partnership with Regeneron ends or stalls materially
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state indicates a cautious approach, as recent financial performance has been weak compared to industry peers.
The market seems to be pricing in a high level of fragility due to expensive valuation and weak execution quality. There is an expectations gap, suggesting that current market assumptions may not fully align with the company's recent challenges.
Management is focused on advancing clinical development and expanding collaborations, but recent financial performance has been weak. The near-term risk of missing expectations is low, but the company operates in a high-miss-rate industry.
The long-term thesis hinges on management's ability to execute on clinical milestones and the performance of sector bellwethers. Additionally, any changes in guidance or macroeconomic conditions could significantly impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. The FDA granted Fast Track Designation for Varsetatug masetecan, which is a positive development. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue collaboration with Regeneron on bispecific cancer therapies using Probody platform.
Over the next 1 to 3 years, CTMX's performance will depend on its execution and the broader healthcare sector's momentum. Not investment advice.